Journal
COLLOIDS AND SURFACES B-BIOINTERFACES
Volume 113, Issue -, Pages 269-275Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.colsurfb.2013.09.001
Keywords
Poorly soluble; Nebivolol; Eudragit (R) RS100; Nanoparticles
Funding
- UGC, Government of India
Ask authors/readers for more resources
Nebivolol, a beta-blocker, has been widely used for the treatment of hypertension and cardiovascular diseases; but has drawbacks like poor solubility and bioavailability requiring frequent dosing. The present study attempts to overcome these issues through nanoparticulate delivery system using widely used carrier Eudragit (R) RS100. The solvent evaporation (single emulsion) technique was used for developing nanoparticles. The impact of formulation and process variables on particle size and entrapment efficiency was studied to optimize the formulation. The physico-chemical characterization confirmed the particle size in nano range with smooth and spherical morphology. Further, Fourier transforms infrared (FTIR) spectroscopy and differential scanning calorimetry (DSC) studies confirm compatibility of drug polymer combination. The in vitro drug release study of the prepared nanoparticles showed prolongation of drug release with reduced burst release in comparison with pure drug powder. (C) 2013 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available